456 related articles for article (PubMed ID: 22993390)
1. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.
Tewalt EF; Cohen JN; Rouhani SJ; Guidi CJ; Qiao H; Fahl SP; Conaway MR; Bender TP; Tung KS; Vella AT; Adler AJ; Chen L; Engelhard VH
Blood; 2012 Dec; 120(24):4772-82. PubMed ID: 22993390
[TBL] [Abstract][Full Text] [Related]
2. Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction.
Rouhani SJ; Eccles JD; Riccardi P; Peske JD; Tewalt EF; Cohen JN; Liblau R; Mäkinen T; Engelhard VH
Nat Commun; 2015 Apr; 6():6771. PubMed ID: 25857745
[TBL] [Abstract][Full Text] [Related]
3. Tolerogenic properties of lymphatic endothelial cells are controlled by the lymph node microenvironment.
Cohen JN; Tewalt EF; Rouhani SJ; Buonomo EL; Bruce AN; Xu X; Bekiranov S; Fu YX; Engelhard VH
PLoS One; 2014; 9(2):e87740. PubMed ID: 24503860
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
Okiyama N; Katz SI
J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812
[TBL] [Abstract][Full Text] [Related]
5. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation.
Cohen JN; Guidi CJ; Tewalt EF; Qiao H; Rouhani SJ; Ruddell A; Farr AG; Tung KS; Engelhard VH
J Exp Med; 2010 Apr; 207(4):681-8. PubMed ID: 20308365
[TBL] [Abstract][Full Text] [Related]
6. Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells.
Hirosue S; Vokali E; Raghavan VR; Rincon-Restrepo M; Lund AW; Corthésy-Henrioud P; Capotosti F; Halin Winter C; Hugues S; Swartz MA
J Immunol; 2014 Jun; 192(11):5002-11. PubMed ID: 24795456
[TBL] [Abstract][Full Text] [Related]
7. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.
Buchan S; Manzo T; Flutter B; Rogel A; Edwards N; Zhang L; Sivakumaran S; Ghorashian S; Carpenter B; Bennett C; Freeman GJ; Sykes M; Croft M; Al-Shamkhani A; Chakraverty R
J Immunol; 2015 Jan; 194(1):125-133. PubMed ID: 25404365
[TBL] [Abstract][Full Text] [Related]
8. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.
Vezys V; Penaloza-MacMaster P; Barber DL; Ha SJ; Konieczny B; Freeman GJ; Mittler RS; Ahmed R
J Immunol; 2011 Aug; 187(4):1634-42. PubMed ID: 21742975
[TBL] [Abstract][Full Text] [Related]
9. Reactive glia promote development of CD103
Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
11. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance.
Diehl L; Schurich A; Grochtmann R; Hegenbarth S; Chen L; Knolle PA
Hepatology; 2008 Jan; 47(1):296-305. PubMed ID: 17975811
[TBL] [Abstract][Full Text] [Related]
12. According to Hepatitis C Virus (HCV) Infection Stage, Interleukin-7 Plus 4-1BB Triggering Alone or Combined with PD-1 Blockade Increases TRAF1
Moreno-Cubero E; Subirá D; Sanz-de-Villalobos E; Parra-Cid T; Madejón A; Miquel J; Olveira A; González-Praetorius A; García-Samaniego J; Larrubia JR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093082
[TBL] [Abstract][Full Text] [Related]
13. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
14. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
[TBL] [Abstract][Full Text] [Related]
15. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
16. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade.
Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ
J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863
[TBL] [Abstract][Full Text] [Related]
17. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion.
Hendriks J; Xiao Y; Rossen JW; van der Sluijs KF; Sugamura K; Ishii N; Borst J
J Immunol; 2005 Aug; 175(3):1665-76. PubMed ID: 16034107
[TBL] [Abstract][Full Text] [Related]
18. Programmed cell death protein 1 and vitiligo.
Lin X; Meng X; Song Z
Int J Dermatol; 2019 Sep; 58(9):1102-1103. PubMed ID: 31175670
[No Abstract] [Full Text] [Related]
19. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T cells undergo activation and programmed death-1 repression in the liver of aged Ae2a,b-/- mice favoring autoimmune cholangitis.
Concepcion AR; Salas JT; Sáez E; Sarvide S; Ferrer A; Portu A; Uriarte I; Hervás-Stubbs S; Oude Elferink RP; Prieto J; Medina JF
Oncotarget; 2015 Oct; 6(30):28588-606. PubMed ID: 26396175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
